The Oncogenic Role and Immune Infiltration for CARM1 Identified by Pancancer Analysis

Liu, Kui; Ma, Jing; Jiao, Ao; Mu, Lili; Wang, Yixian; Yue, Qian; Xue, Jing; Zhang, Wei

doi:10.1155/2021/2986444

Cited by 7 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both genetic and epigenetic factors influence tumor development ( 24 ). The frequency of mutation in TRPM8 was investigated using cBioPortal on 10967 samples from 32 studies.…”

Section: Resultsmentioning

confidence: 99%

Comprehensive Pan-Cancer Analysis of TRPM8 in Tumor Metabolism and Immune Escape

Zhang

Qiao

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

BackgroundTransient receptor potential melastatin 8 (TRPM8) modulates tumor biology and sensitivity to treatment. The present study aimed to determine the part it plays in tumor immunity and physiology using pan-cancer analysis.MethodData from the GTEx, CCLE, TISIDB, GSCA, cBioportal, and TCGA databases were collected using Estimate, Scanneo, and GSEA, and the associations between TRPM8 and prognosis, molecular subtypes, mutational burden, microsatellite instability, immune gene functions, and drug sensitivity were analyzed in 33 tumor types.ResultTRPM8 levels were found to be elevated in most tumors, particularly in solid tumors, with variations according to clinical stage. Mutation frequency was greatest in endometrial carcinoma. High levels of TRPM8 were linked to unfavorable prognosis, immune cell infiltration, and the tumor microenvironment, as well as correlating with abnormalities in the transcription levels of genes associated with immunity and DNA repair. TRPM8 was also linked to unfavorable patient outcomes and cancer-associated signaling.ConclusionsTRPM8 is strongly associated with tumor physiology and immunity. The Pan-Cancer analysis suggests the potential of TRPM8 as a treatment target or biomarker for determining the prognosis of a specific type of cancer.

show abstract

“…Both genetic and epigenetic factors influence tumor development ( 24 ). The frequency of mutation in TRPM8 was investigated using cBioPortal on 10967 samples from 32 studies.…”

Section: Resultsmentioning

confidence: 99%

Comprehensive Pan-Cancer Analysis of TRPM8 in Tumor Metabolism and Immune Escape

Zhang

Qiao

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…CARM1 is overexpressed in different tumors and negatively associated with CD8 + T cells. It can also be used as a potent biomarker for pan-cancer prediction ( 77 ). In ovarian cancer, CARM1 acts as a transcriptional activator to promote XBP1 target gene expression.…”

Section: Classification and Biological Functions Of Histone Methyltra...mentioning

confidence: 99%

The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy

Zhang

Chen²,

Liu³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Epigenetic modifications may alter the proliferation and differentiation of normal cells, leading to malignant transformation. They can also affect normal stimulation, activation, and abnormal function of immune cells in the tissue microenvironment. Histone methylation, coordinated by histone methylase and histone demethylase to stabilize transcription levels in the promoter area, is one of the most common types of epigenetic alteration, which gained increasing interest. It can modify gene transcription through chromatin structure and affect cell fate, at the transcriptome or protein level. According to recent research, histone methylation modification can regulate tumor and immune cells affecting anti-tumor immune response. Consequently, it is critical to have a thorough grasp of the role of methylation function in cancer treatment. In this review, we discussed recent data on the mechanisms of histone methylation on factors associated with immune resistance of tumor cells and regulation of immune cell function.

show abstract

“…These findings established a rationale for the immuno-oncology therapy strategies based on PRMTs. To date, several studies have investigated the roles of PRMTs (PRMT1, CADM1, and PRMT7) in ccRCC 29 30 31 . However, the impact of PRMTs on TME characteristics and clinical outcomes of ccRCC patients is still uncertain 32 .…”

Section: Introductionmentioning

confidence: 99%

Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics

Ye,

Tian,

Anwaier

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive urological cancer that originates from the proximal tubular epithelium. As one of the most common post-translational modification, protein arginine methylation plays a pivotal role in various cancer-associated biological functions, especially in cancer immunity. Therefore, constructing a protein arginine methylation-related prognostic signature would be beneficial in guiding better personalized clinical management for patients with ccRCC. Methods: Based on the multi-omics profiling of the expression levels of eight protein arginine methyltransferases (PRMTs) in 763 ccRCC samples (from TCGA, CPTAC, EMBL, and ICGC databases), we established a scoring system with machine-learning algorithms to quantify the modification patterns on clinical and immunological characterizations of individual ccRCC patient, which was termed as PRMTScore. Moreover, we utilized two external clinical cohorts receiving immunotherapy (n=302) to validate the reliability of the PRMTScore system. Multiplex immunohistochemistry (mIHC) was performed to characterize the cellular composition of 30 paired ccRCC samples. The proteomic profiling of 232 ccRCC samples obtained from Fudan University Shanghai Cancer Center (FUSCC) was analyzed to validate the protein expression of PRMT5 in ccRCC. Finally, CCK-8, transwell, and wound healing assays were conducted to elucidate the role of PRMT5 in ccRCC in vitro. Results: A total of 763 ccRCC patients with available multi-omics profiling were stratified into two clusters (PRMTCluster A and B) with distinctive prognosis, genomic alterations, tumor microenvironment (TME) characteristics, and fundamental biological mechanisms. Subsequently, protein arginine methylation-related prognostic signature (PRMTScore) was constructed and consisted of SLC16A12, HRH2, F2RL3, and SAA1. The PRMTScore showed remarkable differences in outcomes, immune and stromal fractions, expressions of immune checkpoints, the abundance of immune cells, and immunotherapy response in ccRCC patients. Additionally, preliminary insights unveiled the tumor-suppressive role of PRMT5 in ccRCC, and the signal of PRMT5 low significantly predicted aggressive prognosis and the high abundance of PD1 + CD8 + cells in ccRCC. Conclusion:We constructed a PRMTScore system, which showed the potent ability to assess the prognosis, TME characteristics, and immunotherapy response for patients with ccRCC. Moreover, this is the first study to propose that PRMT5 acts as a cancer suppressor in ccRCC.

show abstract

The Oncogenic Role and Immune Infiltration for CARM1 Identified by Pancancer Analysis

Cited by 7 publications

References 47 publications

Comprehensive Pan-Cancer Analysis of TRPM8 in Tumor Metabolism and Immune Escape

Comprehensive Pan-Cancer Analysis of TRPM8 in Tumor Metabolism and Immune Escape

The role of histone methylase and demethylase in antitumor immunity: A new direction for immunotherapy

Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics

Contact Info

Product

Resources

About